Free Trial
NASDAQ:AMRX

Amneal Pharmaceuticals (AMRX) Stock Price, News & Analysis

Amneal Pharmaceuticals logo
$9.52 -0.03 (-0.29%)
As of 09:59 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Amneal Pharmaceuticals Stock (NASDAQ:AMRX)

Key Stats

Today's Range
$9.51
$9.58
50-Day Range
$7.82
$9.59
52-Week Range
$6.68
$9.79
Volume
26,639 shs
Average Volume
1.66 million shs
Market Capitalization
$2.99 billion
P/E Ratio
953.95
Dividend Yield
N/A
Price Target
$11.60
Consensus Rating
Buy

Company Overview

Amneal Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

AMRX MarketRank™: 

Amneal Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 362nd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Amneal Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Amneal Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Amneal Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Amneal Pharmaceuticals are expected to grow by 13.21% in the coming year, from $0.53 to $0.60 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Amneal Pharmaceuticals is 955.96, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.75.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Amneal Pharmaceuticals is 955.96, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.26.

  • Percentage of Shares Shorted

    3.42% of the float of Amneal Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amneal Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Amneal Pharmaceuticals has recently decreased by 8.87%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Amneal Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Amneal Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.42% of the float of Amneal Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Amneal Pharmaceuticals has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Amneal Pharmaceuticals has recently decreased by 8.87%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Amneal Pharmaceuticals has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Amneal Pharmaceuticals this week, compared to 6 articles on an average week.
  • Search Interest

    8 people have searched for AMRX on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Amneal Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,700,624.00 in company stock.

  • Percentage Held by Insiders

    26.56% of the stock of Amneal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 31.82% of the stock of Amneal Pharmaceuticals is held by institutions.

  • Read more about Amneal Pharmaceuticals' insider trading history.
Receive AMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amneal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AMRX Stock News Headlines

This is my Christian duty
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.tc pixel
1 Value Stock to Keep an Eye On and 2 Facing Challenges
See More Headlines

AMRX Stock Analysis - Frequently Asked Questions

Amneal Pharmaceuticals' stock was trading at $7.92 at the beginning of 2025. Since then, AMRX shares have increased by 20.6% and is now trading at $9.55.

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) issued its quarterly earnings results on Tuesday, August, 5th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a negative trailing twelve-month return on equity of 189.49% and a net margin of 0.12%.
Read the conference call transcript
.

Top institutional investors of Amneal Pharmaceuticals include Rubric Capital Management LP (3.74%), Nantahala Capital Management LLC (1.39%), Geode Capital Management LLC (1.20%) and BlackBarn Capital Partners LP (1.10%). Insiders that own company stock include Tushar Bhikhubhai Patel, Tpg Gp A, Llc, Gautam Patel, John Kiely, Andrew S Boyer, Nikita Shah and Jason B Daly.
View institutional ownership trends
.

Shares of AMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Amneal Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), TotalEnergies (TTE), Voyager Therapeutics (VYGR), Broadcom (AVGO) and Waste Connections (WCN).

Company Calendar

Last Earnings
8/05/2025
Today
8/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AMRX
Previous Symbol
NASDAQ:AMRX
CIK
1723128
Employees
8,100
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$11.00
Potential Upside/Downside
+21.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.01
Trailing P/E Ratio
955.96
Forward P/E Ratio
18.02
P/E Growth
N/A
Net Income
-$116.89 million
Net Margins
0.12%
Pretax Margin
3.13%
Return on Equity
-189.49%
Return on Assets
6.17%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.43
Quick Ratio
0.88

Sales & Book Value

Annual Sales
$2.79 billion
Price / Sales
1.07
Cash Flow
$1.42 per share
Price / Cash Flow
6.74
Book Value
($0.36) per share
Price / Book
-26.53

Miscellaneous

Outstanding Shares
314,080,000
Free Float
230,660,000
Market Cap
$3.00 billion
Optionable
Optionable
Beta
1.11

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:AMRX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners